KARD

Kardigan, Inc.

Healthcare · Biotechnology

14.80$ -0.1% vs. previous close Closing price · As of: Sep 28, 2026

Statements

Income Statement

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures per share in USD.

Tick rows to compare them in a chart (up to 4)

Income Statement KARD
Line item	2024	2025
Revenue	0.00	0.00
Research & Development	0.94	2.55
Selling, General & Administrative	0.14	0.81
Total Operating Expenses	1.08	3.37
Operating Income	-1.08	-3.37
Pre-Tax Income	-0.99	-3.28
Income Tax Expense	–	-0.08
Net Income	-0.99	-3.20
EBITDA	–	-3.27

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.